About Contact Find a supplier
Join the Index

Capability

Biopharmaceutical manufacturing in Singapore

Manufacture of biologic drug substance — monoclonal antibodies, recombinant and fusion proteins, and vaccines — grown in mammalian cell culture or microbial fermentation, purified and released as bulk. Buyers select on modality, expression system and bioreactor fleet, captive-versus-CDMO model, and FDA, EMA and HSA inspection record under PIC/S GMP.

Biologics drug-substance manufacturing is the crown jewel of Singapore's biomedical economy, and it is the pillar the record has until now been missing. This is the making of the active biologic itself — monoclonal antibodies, recombinant and fusion proteins, and vaccines — grown in mammalian cell culture or microbial fermentation, purified, and released as bulk drug substance. Singapore's biomedical-sciences manufacturing output runs to roughly S$18 billion a year, eight of the world's top ten biopharmaceutical companies operate plants here, and the sector employs 9,000-plus manufacturing professionals. The anchor is Tuas Biomedical Park — a 371-hectare JTC estate whose plug-and-play plots host some 14 global biomedical manufacturers and about 7,000 workers, with Amgen, GSK, Novartis, Roche, AbbVie, Lonza and Sanofi among the tenants. Every plant is gated by the Health Sciences Authority (HSA), which licenses therapeutic-product manufacture (TPML) to PIC/S GMP standard — Singapore has been a PIC/S member since 2000, and that regulatory credibility is a large part of why the MNCs site drug substance here rather than in cheaper geographies.

The buyer's read on a biologics plant is specific: the modality (mAb, recombinant protein, vaccine, and increasingly bispecifics and bioconjugates); the expression system and bioreactor fleet — stainless-steel scale (Lonza runs 20,000-litre suites) versus single-use flexibility (2,000-litre trains); whether the site is captive (an MNC making its own products) or a CDMO selling capacity to third parties; and its regulatory track record of FDA/EMA/HSA inspections. The field splits three ways. Captive MNC plants dominate the installed base — Amgen's next-generation biomanufacturing site, GSK's vaccines complex, Novartis's and Roche's cell-culture plants, AbbVie's biologics expansion and Sanofi's modular vaccine facility. Global CDMOs — Lonza and WuXi Biologics (the latter building a roughly US$1.4 billion, 13.5-hectare CRDMO adding 120,000 litres of capacity) — sell drug-substance capacity at scale. And a thin homegrown / emerging tier — Esco Aster and Hilleman Laboratories — anchors multi-modality and vaccine development. The structural shift is a decisive tilt of new capacity toward biologics, with fresh multi-hundred-million-dollar commitments landing almost yearly.

Also known as: biologics manufacturing · biologics drug substance manufacturing · biopharmaceutical CDMO · cell culture manufacturing · monoclonal antibody manufacturing · vaccine manufacturing

Capability specifications

Modalities
Monoclonal antibodies, recombinant and fusion proteins, vaccines, bispecifics
Production systems
Mammalian cell culture, microbial fermentation
Bioreactor scale
Stainless-steel to 20,000 L; single-use trains to 2,000 L
Regulatory
HSA therapeutic-product manufacturer's licence (TPML); PIC/S GMP; FDA/EMA inspection
Model
Captive MNC plant or contract (CDMO) capacity

Companies with this capability in Singapore

ENQUIRE

Not sure which supplier?

Tell the Singapore Industry Index what you need — this enquiry is tagged to Biopharmaceutical manufacturing — and we'll point you to the companies on the record that do it. To reach one company directly, enquire from its profile above.